Search results for "circulating"

showing 10 items of 173 documents

Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and C…

2022

Abstract Purpose: Sensitive methods for risk stratification, monitoring therapeutic efficacy, and early relapse detection may have a major impact on treatment decisions and patient management for stage III colorectal cancer patients. Beyond assessing the predictive power of postoperative ctDNA detection, we explored the added benefits of serial analysis: assessing adjuvant chemotherapy (ACT) efficacy, early relapse detection, and ctDNA growth rates. Experimental Design: We recruited 168 patients with stage III colorectal cancer treated with curative intent at Danish and Spanish hospitals between 2014 and 2019. To quantify ctDNA in plasma samples (n = 1,204), 16 patient-specific somatic sing…

MaleOncologyCancer Researchmedicine.medical_specialtyNeoplasm ResidualAdjuvant chemotherapyClinical Decision-MakingCirculating Tumor DNAText miningPredictive Value of TestsInternal medicineBiomarkers TumorStage III colorectal cancermedicineAdjuvant therapyHumansTumor growthAgedNeoplasm Stagingbusiness.industryPrognosisMinimal residual diseaseConfidence intervalOncologyCirculating tumor DNAFemaleDrug MonitoringNeoplasm Recurrence LocalColorectal NeoplasmsbusinessClinical Cancer Research
researchProduct

Characterization of human infiltrating and circulating gamma-delta T cells in prostate cancer

2019

Purpose The aim of our study was to prospectively evaluate the distribution of gamma-delta (γδ)1 and γδ2 T cells and their phenotypes in peripheral blood and prostate samples of patients diagnosed with or without prostate cancer (PCa) at prostate biopsy. Materials and methods A consecutive series of 43 outpatients underwent trans-rectal echo-guided prostate biopsy for suspected PCa. Flow cytometry analysis was used to identify and characterize the γδ T cells populations in peripheral blood and tissue samples. Patients were stratified according to the presence or not of PCa, and its International Society of Urological Pathology (ISUP) grade (1 vs. ≥2). Results The distribution of γδ T cells …

MalePathologymedicine.medical_specialtyProstate biopsyT-Lymphocyte subsetUrological OncologyBiopsyUrology030232 urology & nephrologylcsh:RC870-923Flow cytometry03 medical and health sciencesProstate cancerLymphocytes Tumor-Infiltrating0302 clinical medicineProstateBiopsymedicineHumansProspective StudiesIntraepithelial LymphocytesAgedNeoplasm gradingmedicine.diagnostic_testbusiness.industryCancerMiddle AgedNeoplastic Cells Circulatinglcsh:Diseases of the genitourinary system. Urologymedicine.diseasePhenotypeImmunologic surveillanceImmunosurveillancemedicine.anatomical_structure030220 oncology & carcinogenesisOriginal ArticleProstatic neoplasmsProstatic neoplasmbusinessT-Lymphocyte subsetsInvestigative and Clinical Urology
researchProduct

Detection of circulating prostate cells by reverse transcriptase-polymerase chain reaction of human glandular kallikrein (hK2) and prostate-specific …

1997

Abstract Objectives To investigate the clinical value of human glandular kallikrein (hK2) reverse transcriptase-polymerase chain reaction (RT-PCR) for detection of prostate cells in circulation and to compare the results with those obtained from prostate-specific antigen (PSA) RT-PCR. Methods We examined peripheral blood (PB) and bone marrow (BM) samples of 13 patients with advanced-stage prostate cancer and 63 patients with clinically localized disease for the presence of circulating prostate cells. An RT-PCR protocol with a two-step amplification cycle and hot-start conditions was used. Results The limit of detection of the PCR portion is similar for PSA and hK2 (5 to 10 copies of the pla…

MalePathologymedicine.medical_specialtyUrologyurologic and male genital diseasesPolymerase Chain ReactionPeripheral blood mononuclear cellProstate cancerAntigenProstateLNCaPHumansMedicineRNA MessengerHuman Glandular Kallikreinbusiness.industryProstatic NeoplasmsProstate-Specific AntigenNeoplastic Cells Circulatingmedicine.diseaseMolecular biologyProstate-specific antigenmedicine.anatomical_structureKallikreinsBone marrowbusinessTissue KallikreinsUrology
researchProduct

Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus

2016

Genetic changes involved in the metaplastic progression from squamous esophageal mucosa toward Barrett's metaplasia and adenocarcinoma are almost unknown. Several evidences suggest that some miRNAs are differentially expressed in Barrett's esophagus (BE) and esophageal adenocarcinoma. Among these, miR-143, miR-145, miR-194, miR-203, miR-205, miR-215 appear to have a key role in metaplasia and neoplastic progression. The aim of this study was to analyze deregulated miRNAs in serum and esophageal mucosal tissue biopsies to identify new biomarkers that could be associated with different stages of esophageal disease. Esophageal mucosal tissue biopsies and blood samples were collected and analyz…

MalePathologymedicine.medical_specialtyesophagitisEsophageal NeoplasmsSettore MED/06 - Oncologia MedicaSettore BIO/11 - Biologia MolecolareColumnar-lined oesophaguAdenocarcinomaSettore MED/08 - Anatomia PatologicaEsophageal Diseases03 medical and health sciencesBarrett's esophagus0302 clinical medicineMetaplasiamicroRNAmedicineHumansCirculating MicroRNAEsophagusMetaplasiamicroRNAbusiness.industryEsophageal diseaseEsophagitiBarrett's esophagus; Columnar-lined oesophagus; Esophagitis; Metaplasia; microRNA; OncologyBarrett's esophaguMiddle Agedmedicine.diseaseCirculating MicroRNAmedicine.anatomical_structureOncology030220 oncology & carcinogenesisBarrett's esophaguscolumnar-lined oesophagusDisease ProgressionAdenocarcinoma030211 gastroenterology & hepatologyFemalemedicine.symptombusinessEsophagitisResearch Paper
researchProduct

Comparative Analysis of Chromatin-Delivered Biomarkers in the Monitoring of Sepsis and Septic Shock: A Pilot Study

2021

Sepsis management remains one of the most important challenges in modern clinical practice. Rapid progression from sepsis to septic shock is practically unpredictable, hence the critical need for sepsis biomarkers that can help clinicians in the management of patients to reduce the probability of a fatal outcome. Circulating nucleoproteins released during the inflammatory response to infection, including neutrophil extracellular traps, nucleosomes, and histones, and nuclear proteins like HMGB1, have been proposed as markers of disease progression since they are related to inflammation, oxidative stress, endothelial damage, and impairment of the coagulation response, among other pathological…

MalePilot Projectslaw.inventionCohort StudiesHistonessepsisMicelawHMGB1 ProteinBiology (General)SpectroscopyImmunoassayHMGB1biologyCommunicationAntibodies MonoclonalGeneral MedicineMiddle AgedIntensive care unitShock SepticChromatinComputer Science ApplicationsChemistryCohortFemaleELISAmedicine.symptomcirculating histonesmedicine.medical_specialtyQH301-705.5InflammationHMGB1CatalysisInorganic ChemistrySepsismedicineAnimalsHumansPhysical and Theoretical ChemistryIntensive care medicineMolecular BiologyPathologicalQD1-999Septic shockbusiness.industryOrganic ChemistrybiomarkersNeutrophil extracellular trapsmedicine.diseaseNucleoproteinsnucleosomesbiology.proteinCitrullineseptic shockbusinessInternational Journal of Molecular Sciences
researchProduct

KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer.

2018

Abstract There are limited data on circulating, cell-free, tumour (ct)DNA analysis in locally advanced rectal cancer (LARC). Digital droplet (dd)PCR was used to investigate KRAS/BRAF mutations in ctDNA from baseline blood samples of 97 LARC patients who were treated with CAPOX followed by chemoradiotherapy, surgery and adjuvant CAPOX ± cetuximab in a randomised phase II trial. KRAS mutation in G12D, G12V or G13D was detected in the ctDNA of 43% and 35% of patients with tumours that were mutant and wild-type for these hotspot mutations, respectively, according to standard PCR-based analyses on tissue. The detection rate in the ctDNA of 10 patients with less common mutations was 50%. In 26 ca…

MaleProto-Oncogene Proteins B-rafOrganoplatinum CompoundsScienceCetuximabArticleCirculating Tumor DNAProto-Oncogene Proteins p21(ras)SDG 3 - Good Health and Well-beingAntineoplastic Combined Chemotherapy ProtocolsJournal ArticleHumansneoplasmsCapecitabineDigestive System Surgical ProceduresAgedRectal NeoplasmsQRChemoradiotherapy AdjuvantMiddle AgedPrognosisdigestive system diseasesOxaliplatinTreatment OutcomeMutation/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingMedicineFemaleScientific reports
researchProduct

AR-V7 Protein Expression in Circulating Tumour Cells Is Not Predictive of Treatment Response in mCRPC

2019

<b><i>Introduction:</i></b> Androgen receptor variant 7 (AR-V7) plays an important role in the progression of castration-resistant prostate cancer (CRPC) and has shown potential as a predictive biomarker in circulating tumour cells (CTCs) isolated from the bloodstream in terms of a liquid biopsy. Studies have shown that AR-V7 is a potential surrogate for selecting drug classes for systemic treatment by detecting nuclear AR-V7 by immunofluorescence or measuring AR-V7 messenger RNA by quantitative PCR. Here, we assessed the predictive value of AR-V7 detected by classical immunohistochemistry (IHC) for treatment response. <b><i>Methods:</i></b> C…

MaleUrology030232 urology & nephrologyAntineoplastic AgentsDocetaxel03 medical and health scienceschemistry.chemical_compoundProstate cancer0302 clinical medicineCell Line TumormedicineHumansEnzalutamideProspective StudiesLiquid biopsyAgedAged 80 and overbusiness.industryAndrogen AntagonistsNeoplastic Cells CirculatingPrognosismedicine.diseaseAndrogen receptorProstatic Neoplasms Castration-ResistantTreatment OutcomeDocetaxelchemistryReceptors AndrogenCabazitaxel030220 oncology & carcinogenesisCancer researchBiomarker (medicine)ImmunohistochemistryTaxoidsbusinessmedicine.drugUrologia Internationalis
researchProduct

Circulating MicroRNAs in Extracellular Vesicles as Potential Biomarkers of Alcohol-Induced Neuroinflammation in Adolescence: Gender Differences

2020

Current studies evidence the role of miRNAs in extracellular vesicles (EVs) as key regulators of pathological processes, including neuroinflammation and neurodegeneration. As EVs can cross the blood&ndash

Maleadolescent micelcsh:ChemistryMiceAlcohol intoxicationCAMK2Alcsh:QH301-705.5SpectroscopyBrain DiseasesSex CharacteristicsNeurodegenerationfood and beveragesBrainGeneral MedicineComputer Science Applicationsgender differencesmiRNAsFemalemedicine.symptomextracellular vesiclesadolescent humansmedicine.medical_specialtyAdolescentInflammationBrain damageArticleCatalysisInorganic ChemistryExtracellular VesiclesInternal medicinemicroRNAmedicineAnimalsHumansCirculating MicroRNAPhysical and Theoretical ChemistryMolecular BiologyNeuroinflammationInflammationEthanolbusiness.industryOrganic Chemistrybiomarkersmedicine.diseaseMice Inbred C57BLCirculating MicroRNAEndocrinologylcsh:Biology (General)lcsh:QD1-999inflammationethanolbusinessInternational Journal of Molecular Sciences
researchProduct

Zoledronic acid induces a significant decrease of circulating endothelial cells and circulating endothelial precursor cells in the early prostate can…

2012

<b><i>Purpose:</i></b> Published data demonstrated that zoledronic acid (ZOL) exhibits antiangiogenetic effects. A promising tool for monitoring antiangiogenic therapies is the measurement of circulating endothelial cells (CECs) and circulating endothelial precursor cells (CEPs) in the peripheral blood of patients. Our aim was to investigate the effects of ZOL on levels of CECs and CEPs in localized prostate cancer. <b><i>Methods:</i></b> Ten consecutive patients with a histologic diagnosis of low-risk prostate adenocarcinoma were enrolled and received an intravenous infusion of ZOL at baseline (T0), 28 days (T28) and 56 days (T56). Blood samp…

Malemedicine.medical_specialtyPathologyCancer ResearchBone Density Conservation AgentAngiogenesismedicine.medical_treatmentUrologyAngiogenesis InhibitorsAngiogenesis; Circulating endothelial cells; Circulating endothelial precursor cells; Prostate cancer; Zoledronic acid; Aged; Angiogenesis Inhibitors; Bone Density Conservation Agents; Cell Movement; Diphosphonates; Endothelial Cells; Humans; Imidazoles; Male; Middle Aged; Neoadjuvant Therapy; Prostatic Neoplasms; Stem Cells; Medicine (all); Oncology; Cancer ResearchFlow cytometryProstate cancerCirculating endothelial cellCell MovementStem CellPrecursor cellMedicineHumansImidazoleNeoadjuvant therapyZoledronic acidAgedEndothelial CellProstate cancermedicine.diagnostic_testBone Density Conservation AgentsDiphosphonatesbusiness.industryStem CellsMedicine (all)ImidazolesEndothelial CellsProstatic NeoplasmsGeneral MedicineMiddle Agedmedicine.diseasePeripheral bloodNeoadjuvant TherapyAngiogenesiZoledronic acidDiphosphonateOncologyCirculating endothelial precursor cellProstatic NeoplasmStem cellbusinessmedicine.drugAngiogenesis InhibitorHuman
researchProduct

Urokinase-plasminogen-activator receptor expression in disseminated tumour cells in the bone marrow and peripheral blood of patients with clinically …

2009

OBJECTIVE To evaluate the expression of urokinase-plasminogen-activator receptor (uPA-R) in disseminated tumour cells (DTC) in bone marrow (BM) and peripheral blood (PB) of patients with clinically localized prostate cancer before radical prostatectomy (RP), and to assess the associations with pathological variables and prognosis. PATIENTS AND METHODS In all, 52 patients (47 with clinically localized cancer and five with benign prostatic hyperplasia, BPH, as controls) were prospectively enrolled. BM and PB samples were drawn before surgery. DTC were enriched using a commercial system, cytokeratin (CK) 8/18 was used to detect DTC, and uPA-R expression was detected by dual-immunostaining of t…

Malemedicine.medical_specialtyPathologyUrologyReceptor expressionmedicine.medical_treatmentGastroenterologyReceptors Urokinase Plasminogen ActivatorCytokeratinProstate cancerBone MarrowInternal medicinemedicineBiomarkers TumorHumansAgedProstatectomybusiness.industryProstatectomyCancerProstatic NeoplasmsHyperplasiaMiddle AgedProstate-Specific Antigenmedicine.diseaseNeoplastic Cells CirculatingPrognosisImmunohistochemistryUrokinase receptormedicine.anatomical_structureLymphatic MetastasisBone marrowNeoplasm Recurrence LocalbusinessEpidemiologic MethodsBJU international
researchProduct